NCT05518253View on ClinicalTrials.gov

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions
Metastatic TumorAdvanced Solid TumorRenal Cell CarcinomaOvarian CancerCervix Cancer
Interventions
BIOLOGICAL

CD70 CAR-T cells

Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

BIOLOGICAL

CD70 CAR-T cells

Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

310006

RECRUITING

First affiliated hospital, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Chongqing Precision Biotech Co., Ltd

INDUSTRY

lead

Weijia Fang, MD

OTHER